

**In the Claims:**

Please cancel claims 1 and 4 without prejudice to the filing of a continuing application.

Please rewrite claims 2, 3, and 5 to read as follows:

---

2. (once amended) A method of inhibiting graft versus host disease in a mammal requiring donor lymphocyte infusion, said method comprising:

a) contacting the donor lymphocytes to be infused with an aqueous solution containing a therapeutically effective amount of L-leucyl-L-leucine methyl ester ex vivo;

b) selectively eliminating cytotoxic T-cells;

c) infusing said donor lymphocytes into said mammal; and

d) inhibiting graft versus host disease,

wherein said mammal requires donor lymphocyte infusion following allogeneic T cell-depleted hematopoietic stem cell transplantation.

A1

3. (once amended) A method of inhibiting graft versus host disease in a mammal requiring donor lymphocyte infusion, said method comprising:

a) contacting the donor lymphocytes to be infused with an aqueous solution containing a therapeutically effective amount of L-leucyl-L-leucine methyl ester ex vivo;

b) selectively eliminating cytotoxic T-cells;

c) infusing said donor lymphocytes into said mammal; and

d) inhibiting graft versus host disease,

wherein said infusing of said donor lymphocytes into said mammal occurs after donor hematopoietic stem cell engraftment.

---

5. (once amended) A method of inhibiting graft versus host disease in a mammal requiring transplant of CD34<sup>+</sup> stem cells, said method comprising:

A2

- A2
- a) obtaining a preparation of hematopoietic stem cells from a mammal;
  - b) separating said hematopoietic stem cells to be infused into CD34<sup>+</sup> and CD34<sup>-</sup> fractions;
  - c) contacting said CD34<sup>-</sup> hematopoietic stem cell fraction with an aqueous solution containing a therapeutically effective amount of L-leucyl-L-leucine methyl ester *ex vivo*;
  - d) selectively eliminating cytotoxic T-cells in the CD34<sup>-</sup> hematopoietic stem cell fraction;
  - e) co-administering a therapeutically effective amount of said L-leucyl-L-leucine methyl ester-treated CD34<sup>-</sup> hematopoietic stem cell fraction with said CD34<sup>+</sup> hematopoietic stem cell fraction; and
  - f) inhibiting graft versus host disease.
- 

Please add the following new claims 6 to 11:

---

6. (new) The method according to any one of claims 2, 3, or 5, wherein said mammal is a human.

A3

7. (new) The method according to any one of claims 2, 3, or 5, wherein said therapeutically effective amount of L-leucyl-L-leucine methyl ester is at least one micromolar.

8. (new) The method according to any one of claims 2, 3, or 5, wherein said therapeutically effective amount of L-leucyl-L-leucine methyl ester is from about 10 micromolar to about 500 micromolar.

9. (new) The method according to any one of claims 2, 3, or 5, wherein said therapeutically effective amount of L-leucyl-L-leucine methyl ester is at least about 500 micromolar.

10. (new) The method according to any one of claims 2, 3, or 5, wherein said contact is for at least 15 minutes.